Abstract LB169: Establishment of patient-derived organoid (PDO) from single cell-originated core-needle biopsied (CNB) samples of breast cancer

IF 12.5 1区医学 Q1 ONCOLOGY

Cancer research Pub Date : 2025-04-25 DOI:10.1158/1538-7445.am2025-lb169

Wen-Hung Kuo, Jia-Yang Chen, Chia-Chun Liu, Mark D. Pegram, Yu-Min Lin, Chia-Yuan Chang, Ying-Chih Chang

{"title":"Abstract LB169: Establishment of patient-derived organoid (PDO) from single cell-originated core-needle biopsied (CNB) samples of breast cancer","authors":"Wen-Hung Kuo, Jia-Yang Chen, Chia-Chun Liu, Mark D. Pegram, Yu-Min Lin, Chia-Yuan Chang, Ying-Chih Chang","doi":"10.1158/1538-7445.am2025-lb169","DOIUrl":null,"url":null,"abstract":"Breast cancer (BC) exhibits differential subtypes with morphological and genetic heterogeneity. Lack of adequate ex vivo model and relevant PDO bank limits following clinical and applications and anti-cancer developments. Three-dimensional cell cultures, such as tumor spheroids, offered a promising alternative tool to reduce animal testing and act as patient avatar for cancer research. However, current platforms, such as scaffold-free low-adherence attachment plates, face challenges with low efficiency of spheroid formation and suffocate in handling rare cell samples. To address this issue, we employed the R3CE platform (Rapid, Reproducible, Rare Cell 3D Expansion; AcroCyte Therapeutics) to facilitate PDO cultivation and establishment including CNB samples based on single cell-derived 3D culture. Paired total 23 normal, 22 tumor, and 14 lymph node CNB tissue samples from various subtypes of cancer patients were collected for PDO culture. Observations revealed varied morphologies in paired normal versus tumor PDOs after culture. The overall successful rate was 84% (93% exclude lymph node) with normal PDO achieving 100% (23/23) success and tumor PDO culture reaches 86% (19/22) successful rate. Lymph node cultures on PDO had a success rate of 57% (8/14) due to potential sentinel node evaluation during routine examination. The established PDOs were confirmed by IHC staining for ER, PR, or Her2 expression. The tumorigenicity of the tumor PDOs was also validated through in vivo xenograft formation with pathology verified histological appearance. Our results demonstrate a streamlined procedures on amplification and establishment, enhancing PDOs model development and further clinical applications. Citation Format: Wen-Hung Kuo, Jia-Yang Chen, Chia-Chun Liu, Mark D. Pegram, Yu-Min Lin, Chia-Yuan Chang, Ying-Chih Chang. Establishment of patient-derived organoid (PDO) from single cell-originated core-needle biopsied (CNB) samples of breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 2 (Late-Breaking, Clinical Trial, and Invited s); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_2): nr LB169.","PeriodicalId":9441,"journal":{"name":"Cancer research","volume":"29 1","pages":""},"PeriodicalIF":12.5000,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1158/1538-7445.am2025-lb169","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Breast cancer (BC) exhibits differential subtypes with morphological and genetic heterogeneity. Lack of adequate ex vivo model and relevant PDO bank limits following clinical and applications and anti-cancer developments. Three-dimensional cell cultures, such as tumor spheroids, offered a promising alternative tool to reduce animal testing and act as patient avatar for cancer research. However, current platforms, such as scaffold-free low-adherence attachment plates, face challenges with low efficiency of spheroid formation and suffocate in handling rare cell samples. To address this issue, we employed the R3CE platform (Rapid, Reproducible, Rare Cell 3D Expansion; AcroCyte Therapeutics) to facilitate PDO cultivation and establishment including CNB samples based on single cell-derived 3D culture. Paired total 23 normal, 22 tumor, and 14 lymph node CNB tissue samples from various subtypes of cancer patients were collected for PDO culture. Observations revealed varied morphologies in paired normal versus tumor PDOs after culture. The overall successful rate was 84% (93% exclude lymph node) with normal PDO achieving 100% (23/23) success and tumor PDO culture reaches 86% (19/22) successful rate. Lymph node cultures on PDO had a success rate of 57% (8/14) due to potential sentinel node evaluation during routine examination. The established PDOs were confirmed by IHC staining for ER, PR, or Her2 expression. The tumorigenicity of the tumor PDOs was also validated through in vivo xenograft formation with pathology verified histological appearance. Our results demonstrate a streamlined procedures on amplification and establishment, enhancing PDOs model development and further clinical applications. Citation Format: Wen-Hung Kuo, Jia-Yang Chen, Chia-Chun Liu, Mark D. Pegram, Yu-Min Lin, Chia-Yuan Chang, Ying-Chih Chang. Establishment of patient-derived organoid (PDO) from single cell-originated core-needle biopsied (CNB) samples of breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 2 (Late-Breaking, Clinical Trial, and Invited s); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_2): nr LB169.

查看原文本刊更多论文

LB169：从乳腺癌单细胞源性核心针活检（CNB）样本中建立患者源性类器官（PDO）

乳腺癌（BC）表现出形态学和遗传异质性的不同亚型。缺乏足够的离体模型和相关的PDO库限制后，临床应用和抗癌发展。三维细胞培养，如肿瘤球体，提供了一个有前途的替代工具，以减少动物试验和作为癌症研究的病人化身。然而，目前的平台，如无支架的低粘附性附着板，面临着球体形成效率低和在处理稀有细胞样品时难以处理的挑战。为了解决这个问题，我们采用了R3CE平台(Rapid, reproducibility, Rare Cell 3D Expansion；AcroCyte Therapeutics)，以促进PDO的培养和建立，包括基于单细胞衍生3D培养的CNB样品。收集不同亚型癌症患者的23例正常、22例肿瘤和14例淋巴结CNB组织标本进行PDO培养。观察发现配对的正常PDOs与肿瘤PDOs在培养后形态不同。总成功率为84%（排除淋巴结为93%），正常PDO 100%(23/23)，肿瘤PDO培养86%（19/22）。由于常规检查中对潜在前哨淋巴结的评估，PDO淋巴结培养成功率为57%（8/14）。建立的PDOs通过免疫组化染色确认ER、PR或Her2的表达。肿瘤PDOs的致瘤性也通过体内异种移植物形成和病理证实的组织学外观得到证实。我们的结果证明了一个简化的扩增和建立程序，促进了PDOs模型的开发和进一步的临床应用。引用格式：郭文鸿，陈家阳，刘家春，Mark D. Pegram，林玉敏，张佳远，张颖芝。从单细胞来源的核心针活检（CNB）乳腺癌样本中建立患者来源的类器官（PDO）[摘要]。摘自：《2025年美国癌症研究协会年会论文集》；第二部分（最新进展，临床试验，并邀请s）；2025年4月25日至30日；费城（PA）： AACR；中国癌症杂志，2015;35(8):391 - 391。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer research 医学-肿瘤学

CiteScore

16.10

自引率

0.90%

发文量

7677

审稿时长

2.5 months

期刊介绍： Cancer Research, published by the American Association for Cancer Research (AACR), is a journal that focuses on impactful original studies, reviews, and opinion pieces relevant to the broad cancer research community. Manuscripts that present conceptual or technological advances leading to insights into cancer biology are particularly sought after. The journal also places emphasis on convergence science, which involves bridging multiple distinct areas of cancer research. With primary subsections including Cancer Biology, Cancer Immunology, Cancer Metabolism and Molecular Mechanisms, Translational Cancer Biology, Cancer Landscapes, and Convergence Science, Cancer Research has a comprehensive scope. It is published twice a month and has one volume per year, with a print ISSN of 0008-5472 and an online ISSN of 1538-7445. Cancer Research is abstracted and/or indexed in various databases and platforms, including BIOSIS Previews (R) Database, MEDLINE, Current Contents/Life Sciences, Current Contents/Clinical Medicine, Science Citation Index, Scopus, and Web of Science.